[D6]-Ribociclib

Ribociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced metastic breast cancer. It is also being studied as a treatment for other drug-resistant cancers. .Stable isotope labeled active pharmaceutical ingredient (API), stable isotope dilution analysis, internal standard, stable isotope labeled standard (SIL), therapeutic drug monitoring (TDM), quantitative bioanalytical method validation, clinical diagnosis, LC/MS method validation, diagnostic breath test, clinical chemistry, diagnostic tools & biomarkers.